Ken Griffin Dumps SpaceX, Amazon; Buys ARKK and Bets Big on Marvell
Inside Citadel's Q3 13F: Ken Griffin slashed AMD and Amazon, raised Marvell 729%, and quietly unwound Leopold Aschenbrenner's AI fund.
Last updated: 2026-11-17 13:56:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
ABBVIE INC. (ABBV) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NYSE. The stock is currently priced at $292.30, with a market capitalization of $521.50B and a P/E ratio of 50.39. Over the past 52 weeks, its price has ranged from $190.75 to $302.93. This page covers its latest market performance, valuation, price trends and company information.
$521.50B | |
$294.44 | |
$296.22 | |
$292.04 | |
$294.55 | |
7.11K | |
4.81M | |
50.39 | |
$302.93 | |
$190.75 | |
2.33% | |
12-31 |
ABBVIE INC. (ABBV) is trading at $292.30 in pre-market trading as of 2026-11-17 13:54:00, down 0.76% ($2.25) from the previous close of $294.55
Pre-market trading shows how investors are pricing ABBV before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, ABBVIE INC. (ABBV) moved from $291.31 to $292.30, representing a gain of 0.34% ($0.99).
The stock traded between $281.07 and $301.20 during the period. The latest price is near the middle of the 7-day range, indicating range-bound.
The average daily volume was 4.47 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 90.5%
ABBV is currently trading at $292.30, placing it 90.5% of the way from its 52-week low of $190.75 to its 52-week high of $302.93. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio, while the 2026 acquisition of Apogee adds to AbbVie's immunology depth.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 57,000 |
| CEO | Robert A. Michael |
| Founded | 2012 |
| Exchange | NYSE |
| Company Website |
View the latest dividend and stock split events for ABBVIE INC.
Dividend | |
|---|---|
| Ex-Dividend Date | Jan 15, 2027 |
| Payment Date | Feb 16, 2027 |
| Dividend Per Share | $1.82 |
Latest news related to ABBVIE INC. and ABBV stock.
Inside Citadel's Q3 13F: Ken Griffin slashed AMD and Amazon, raised Marvell 729%, and quietly unwound Leopold Aschenbrenner's AI fund.
Commit Biologics completed a $60 million seed financing round led by Ackermans & van Haaren, with participation from AbbVie Ventures and M Ventures. The funds will support IND-enabling activities and clinical development of COM002, its first development candidate, a dual-targeting bispecific complement engager designed for cancer and autoimmune disease treatment.
Three healthcare dividend stocks—AbbVie, Gilead Sciences, and Becton, Dickinson—have significantly outperformed the S&P 500 in 2026, with gains of 29%, 37%, and 43% respectively. All three are recommended as continued buys due to strong underlying businesses, solid dividend programs (two are Dividend Kings), and favorable long-term growth prospects driven by key product pipelines and market tailwinds.
Four sectors are higher and seven are lower in Monday’s regular session, with defensive sectors holding the top three positions. The leaders are clustered rather than widely separated, with the top three staying within a narrow range of one another.
Barclays analyst Emily Field maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $325 to $335.
Eligible investors can buy real shares of ABBVIE INC. (ABBV) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to ABBV, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between ABBV shares and USD.
ABBV Shares to USD
1.00 ABBV shares = 292.3 USD
Calculations are estimates based on the latest available price and are for reference only.